Clinical trials firm Clario has entered into a new strategic partnership with PathAI, to offer a single-vendor solution for efficient anatomical pathology services and next-generation video endoscopy analysis.
This co-delivery model streamlines endoscopic and histopathology endpoints to improve efficiency in global GI studies. CROs and sponsors will benefit from an end-to-end process that covers training, logistics, tissue processing, slide digitisation, image analysis, and data transfers all with the medical and scientific oversight of Clario’s experts. Sites will experience simplified workflows with improved training, reporting, and document management.
"At Clario we have long been at the forefront of supporting GI clinical trials, and we are excited to augment our strengths with PathAI's capabilities in the area of discovery and patient care," said Marcela Vieira MD, Clario's Medical Director of Gastroenterology. "The combination of endoscopy and histopathology promises to unlock new avenues for clinical research, and we are proud to be in this leadership position with our partners at PathAI."
Clario has extensive experience in GI trials, having supported over 130 studies through advanced imaging solutions like endoscopy, MRI, and ultrasound.
PathAI bolsters the partnership with its expert GI pathologist network and cutting-edge anatomical pathology services while optimising specimen handling and histological assessments. Their AI-powered tools enhance UC assessment, minimise variability in histological scoring, and expedite biomarker discovery.
"We're thrilled to partner with Clario to provide a cutting-edge solution for IBD clinical trials," said Matt Grow, Chief Business Officer and President of Biopharma at PathAI. "Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery and therapy development in IBD."